Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
Needham initiated coverage on Praxis Precision Medicines Inc (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engaged in the development of therapies for central nervous system disorders.
尼德姆開始報道Praxis Precision Medicines Inc（納斯達克股票代碼：PRAX），這是一家處於臨床階段的生物製藥公司，從事中樞神經系統疾病療法的開發。
The company's lead product ulixacaltamide for essential tremor (ET) is undergoing Essential3 Phase 3 program, with topline results expected in the second half of 2024 to support a planned New Drug Application (NDA) submission in 2025.
該公司治療特發性震顫（ET）的主要產品尤利沙考他胺正在進行Essential3三期項目，預計將在2024年下半年取得主要結果，以支持計劃於2025年提交的新藥申請（NDA）。
- The analyst writes that sales of Ulixa for essential tremor (ET), if successful in Phase 3, could peak at over $1 billion in 2030 (60% probability of success).
- Needham writes, "value of ulixacaltamide in essential tremor alone is underappreciated at current levels."
- 該分析師寫道，如果在第三階段取得成功，Ulixa治療特發性震顫（ET）的銷售額可能在2030年達到超過10億美元的峯值（成功概率爲60％）。
- 尼德姆寫道：“在目前的水平上，僅在特發性震顫中，ulixacaltamide的價值就被低估了。”
The analyst initiates with a Buy rating and a price target of $145.
分析師最初的評級爲買入，目標股價爲145美元。
The company's second program is PRAX-628 for Focal Onset Seizures.
該公司的第二個項目是針對局竈性發作性癲癇的 PRAX-628。
- Praxis plans to initiate two efficacy studies in focal onset seizures. The first study is expected to begin in the second half of 2024, with topline results expected in 2025, and the second study is expected to initiate in the first half of 2025, with topline results expected in the first half of 2026.
- Praxis計劃啓動兩項針對局竈性發作性癲癇的療效研究。第一項研究預計將於2024年下半年開始，頂線結果預計在2025年開始，第二項研究預計將於2025年上半年啓動，頂線結果預計將在2026年上半年開始。
Praxis anticipates topline results from the Phase 2 EMBOLD study of PRAX-562 for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) in the third quarter of 2024.
Praxis預計，針對 SCN2A 和 SCN8A 發育和癲癇性腦病（DEE）的 PRAX-562 的第二階段 EMBOLD 研究將在 2024 年第三季度取得主要結果。
Praxis is completing multiple global regulatory interactions in the first half of 2024 in anticipation of starting the pivotal phase of the program later in 2024 for Elsunersen (PRAX-222) for SCN2A Gain-of-Function DEEs.
Praxis將在2024年上半年完成多項全球監管互動，預計將在2024年晚些時候啓動Elsunersen（PRAX-222）的 SCN2A 功能增益DEE計劃的關鍵階段。
PRAX-628 in focal epilepsy and elsunersen in SCN2A GoF could drive more than $1.5 billion in peak sales, with an upside from label expansion.
局竈性癲癇中的 PRAX-628 和 SCN2A GoF 中的 elsunersen 可能推動超過15億美元的峯值銷售額，品牌擴張將帶來上行空間。
Praxis' cash runway into 2027 and an early pipeline across the Cerebrum and Solidus platforms can potentially generate significant long-term value.
Praxis進入2027年的現金流以及穿越Cerebrum和Solidus平台的早期渠道有可能產生可觀的長期價值。
Needham adds that positive data from Ulixa Phase 3 and POC for PRAX-562 in the third quarter should continue to drive momentum in Praxis stock.
尼德姆補充說，來自Ulixa第三階段和第三季度的 PRAX-562 POC的積極數據應繼續推動Praxis股票的勢頭。
Price Action: PRAX shares are down 3.44% at $40.27 at the last check on Monday.
價格走勢：週一最後一次支票時，PRAX股價下跌3.44％，至40.27美元。
Photo by PublicDomainPictures from Pixabay
照片由 PublicDomainPictures 從 Pixab